Labcorp Holdings (LH) has been in the spotlight due to a series of notable events and performances. The company reported strong
third-quarter earnings for 2025, managing to beat estimates with impressive
revenue growth and a surging
net margin. Fittingly, Labcorp (LH) shares dipped post-earnings announcement, a typical market reaction. In addition, the company declared a
quarterly dividend of $0.72, a move viewed positively by investors. Furthermore,
Leerink Partnrs and
William Blair increased the FY2025
EPS estimates, while Labcorp saw diagnostic growth and announced its focus on specialty testing and efficiency initiatives. The company's strong Q3 performance was reflected in its
EPS of $3.12 and growth in revenue by 8.6%. Labcorp also upgraded its full-year guidance, signaling confidence in their growth trajectory. It also proposed an
FDA-cleared blood test to rule out Alzheimer's-related amyloid pathology, demonstrating its commitment to innovating and leading in diagnostic applications. Finally, the company acquired select assets of BioReference Health's oncology and clinical testing services, revealing their strategic move towards expanding their market reach in specialty areas.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Sat, 01 Nov 2025 22:57:52 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 5
